Indeed, from a clinical point of view, PCSK9 inhibition induces a dramatic reduction of circulating LDL levels, ranging from 50–60% [213,214] and, importantly, a reduction of about 15% in the risk for major adverse cardiovascular events (MACE) (death from CV causes, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) [210,211], thereby indicating a deep involvement of PCSK9 on the thrombotic process in acute coronary events. Here, PCSK9 is linked to angina pectoris.